<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Schedules of Controlled Substances: Placement of Lasmiditan in Schedule V</h1>
    <p class="timestamp">Published: 2020-01-31 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>On October 11, 2019, the U.S. Food and Drug Administration approved a new drug application for Reyvow (lasmiditan) tablets for oral use. Lasmiditan is chemically known as [2,4,6-trifluoro-N-(6-(1- methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide]. Thereafter, the Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place lasmiditan in schedule V of the Controlled Substances Act (CSA). In accordance with the CSA, as revi...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Rule</p>
    <p><strong>Agency:</strong> Justice Department, Drug Enforcement Administration</p>
    <p><strong>Document Number:</strong> 2020-01957</p>
    <p><strong>Publication Date:</strong> 2020-01-31</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2020/01/31/2020-01957/schedules-of-controlled-substances-placement-of-lasmiditan-in-schedule-v">https://www.federalregister.gov/documents/2020/01/31/2020-01957/schedules-of-controlled-substances-placement-of-lasmiditan-in-schedule-v</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2020-01957</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
